REG - Aptamer Group PLC - Results of 2024 Annual General Meeting

AptamerAnnouncement

29/11/2024 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241129:nRSc2144Oa&default-theme=true

RNS Number : 2144O  Aptamer Group PLC  29 November 2024

 

 

 
 
                                                 29
November 2024

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Results of 2024 Annual General Meeting

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, today announces that the
results of voting on the resolutions put to shareholders at its Annual General
Meeting (AGM) held earlier today at 10:00 am at the offices of Aptamer
Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were
duly passed.

 

Further details of each of the resolutions are set out in the Notice of
Meeting, which was sent to shareholders on 5 November 2024 and the full poll
results will be made available on the Aptamer website later today.

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Adam Dawes 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group plc

 

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and
developers. Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global affinity ligand market is
currently worth over $170 billion.

 

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFKLFLZFLBFBX